🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07776314
Recruiting Observational

Are There Any Clinical Benefits to Screening for Late -Onset Gestational Diabetes Mellitus?"

NCT07776314 · tracked via the Priya Life Science Turkey tracker
Sponsor
Izmir Ataturk Training and Research Hospital
Phase
Observational
Started
2025-03-13
Last updated
2026-08-20

Condition(s) studied

Pregnancy in DiabetesPregnancyPregnancy Outcomes

Study summary

This study aims to screen women who have a negative Gestational diabetes mellitus (GDM) result in routine screening tests or who have never had it with the Fasting Blood Glucose Test (FBG) at 32-34 weeks of gestation to diagnose late-onset GDM with routine FBG ≥5.1 mmol/L (92mg/dl) in fasting blood, and to investigate its connection with perinatal and maternal outcomes, hoping to inform about late-stage GDM.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Gestational Age: Confirmed singleton pregnancy between 32+0 and 34+6 weeks of gestation based on the last menstrual period (LMP) and/or first-trimester crown-rump length (CRL) ultrasound measurement. Follow-up: Intention and willingness to deliver at the study hospital and complete all planned follow-up visits until the end of the postpartum period. Informed Consent: Voluntary agreement to participate in the study evidenced by signed written informed consent. Exclusion Criteria: * Multifetal pregnancies (e.g., twins, triplets) Fetal Anomalies Pre-gestational Chronic Diseases Protocol Non-compliance / Loss to Follow-up Preterm Birth / Preterm Labor

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
İzmir Katip Çelebi Atatürk Training and Research Izmir Karabağlar Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07776314 on ClinicalTrials.gov ↗ ← All trials in Turkey